Gene Transduction of Natural Killer Cells for Clinical Application

Area of Science:

• Immunology
• Cellular Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows success in hematological malignancies.
• Natural killer (NK) cells are being explored as an alternative cellular therapy due to their cytotoxic capacity and unique tumor recognition mechanisms.
• Genetic modification can enhance NK cell tumor-targeting and killing capabilities.

Purpose of the Study:

• To describe a clinically adaptable method for manufacturing genetically modified NK cells.
• To detail the technical procedures for producing enhanced NK cells for therapeutic infusion.
• To comply with current good manufacturing practice (cGMP) regulations for cellular product development.

Main Methods:

• Isolation of peripheral blood mononuclear cells (PBMCs) from leukapheresis products.
• Depletion of T cells from the PBMC population.
• Stimulation and genetic modification (transduction) of NK cells using retroviral vectors.
• Preparation of transduced NK cells for clinical infusion.

Main Results:

• Development of a cGMP-compliant manufacturing process for genetically modified NK cells.
• Detailed description of key procedural steps, including cell isolation, T-cell depletion, and NK cell transduction.
• Establishment of a method for producing NK cells with enhanced anti-tumor potential.

Conclusions:

• Genetically modified NK cells represent a viable and potentially superior alternative to CAR T-cell therapy for certain cancers.
• The described manufacturing process is adaptable for clinical application.
• This work lays the groundwork for the clinical use of enhanced NK cell-based immunotherapies.